Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

If the FDA follows an advisory committee’s vote, it can potentially be a transformative step in the delivery of mental health ...

Iowa and the rest of country is grappling with a worsening physician shortage, resulting in fierce competition for medical ...

With egg prices returning to sky-high levels, there's a major opportunity for plant-based and fermentation-derived ...

In a phase 3 trial, the drug significantly reduced investigator-confirmed HAE attacks per ... FDA last March and the European Commission in August. At the time of the drug’s U.S. approval last y ...

NeuroOne Medical Technologies Corporation ( NASDAQ: NMTC) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET ...

Influenza, COVID-19 and RSV are staples of the winter cold and flu season, but the measles, whooping cough and norovirus are ...

Not only that, but the effect of this specific efficacy endpoint achieved by blarcamesine is numerically superior to that of already approved FDA drugs targeting ... of $399 per year.

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

CR tested 58 dog foods from brands including Blue Buffalo, Hill’s Science Diet, and Purina for key nutrients and dangerous ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...